May 26, 2026
Authored and Edited by Forrest A. Jones; Umber Aggarwal; Candace C. Walther
In Freightcar America, Inc. v. National Steel Car Limited, IPR2025-01047, Director Squires de-instituted an already-instituted IPR after a patent owner filed its patent owner response. The decision rested on the patent owner’s post-institution disclaimer of the claims that formed the basis for institution.
The Board’s institution decision found a reasonable likelihood of unpatentability for claim 24, but not for the remaining challenged claims. Following institution, patent owner disclaimed claim 24 and its dependents and requested Director Review of the decision granting institution of the IPR, arguing that it had disclaimed the claims for which the Board found a reasonable likelihood of unpatentability. Petitioner argued that Director Review is improper when it relies on new evidence—such as a post-institution disclaimer—rather than identifying any error in the Board’s institution decision.
The Director granted review, vacated the decision granting institution, and denied institution. The Director explained that the disclaimed claims “are treated as though they never existed,” citing Federal Circuit precedent. Because the Board had already determined that the petitioner failed to show a reasonable likelihood of success as to any remaining, non-disclaimed claims, the Director found that “maintaining this IPR is an inefficient use of Office resources.”
This decision highlights a strategic path for patent owners to use a targeted disclaimer strategy, coupled with Director Review, to overcome institution of IPR proceedings where institution hinges on only a subset of claims. However, this avenue would seem to only be available if the Office issues a decision explaining its reasons for institution, which, under the current procedure, the Office usually will not. This decision also demonstrates that Director Review of institution remains available even once the IPR is at an advanced stage.
Copyright © 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
At the PTAB Blog
IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026
May 26, 2026
At the PTAB Blog
May 20, 2026
Conference
19th Annual Forum on Pharma & Biotech Patent Litigation in Europe
May 19-20, 2026
Amsterdam
Webinar
Changes at the PTAB from Settled Expectations to Real Parties in Interest to Director Involvement
May 18, 2026
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.